Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Relevance of SARS-CoV-2 related factors ACE2 and TMPRSS2 expressions in gastrointestinal tissue with pathogenesis of digestive symptoms, diabetes-associated mortality, and disease recurrence in COVID-19 patients

Ashutosh Kumar⁹,¹, Muneeb A. Faq¹,²,³, Vikas Pareek⁴,⁵, Khursheed Raza⁶,⁷, Ravi K. Narayana⁹,¹, Pranav Prasoon⁶,⁷, Pavan Kumar⁹,¹, Maheswari Kulandhasamy⁸,⁹, Chiman Kumari⁸,¹, Kamla Kanti¹⁰, Himanshu N. Singh¹¹,¹², Rizwana Qadria¹³, Sada N. Pandey¹⁴,¹⁵, Santosh Kumar⁹,¹

¹ Etiologically Elusive Disorders Research Network (EEDRN), New Delhi, India
² Department of Anatomy, All India Institute of Medical Sciences (AIIMS), Patna, India
³ New York University (NYU) Langone Health Center, NYU Robert I. Grossman School of Medicine, New York, NY, USA
⁴ National Brain Research Center, Manesar, Haryana, India
⁵ Department of Anatomy, All India Institute of Medical Sciences, Deoghar, India
⁶ Pittsburgh Center for Pain Research, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
⁷ Department of Pediatrics, Medical University of South Carolina, Charleston, USA
⁸ Department of Biochemistry, Maulana Azad Medical College (MAMC), New Delhi, India
⁹ Department of Anatomy, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
¹⁰ Department of Microbiology, All India Institute of Medical Sciences (AIIMS), Bathinda, India
¹¹ TAGC-INSERM, U1090, Aix Marseille University, Marseille, France
¹² Neuro-oncology Laboratory, Rockefeller University, New York, NY, USA
¹³ Department of Zoology, Banaras Hindu University (BHU), Varanasi, India
¹⁴ Department of Anesthesiology and Critical Care Medicine, School of Medicine, Johns Hopkins University, Baltimore, USA

ARTICLE INFO

Keywords:
SARS-CoV2
Digestive symptoms
Recurrence
Amino acid transporter
Glucose transporter

ABSTRACT

COVID-19 is caused by a new strain of coronavirus called SARS-coronavirus-2 (SARS-CoV-2), which is a positive sense single strand RNA virus. In humans, it binds to angiotensin converting enzyme 2 (ACE2) with the help a structural protein on its surface called the S-spike. Further, cleavage of the viral spike protein (S) by the proteases like transmembrane serine protease 2 (TMPRSS2) or Cathepsin L (CTSL) is essential to effectuate host cell membrane fusion and virus infectivity. COVID-19 poses intriguing issues with imperative relevancy to clinicians. The pathogenesis of GI symptoms, diabetes-associated mortality, and disease recurrence in COVID-19 are of particular relevance because they cannot be sufficiently explained from the existing knowledge of the viral diseases. Tissue specific variations of SARS-CoV-2 cell entry related receptors expression in healthy individuals can help in understanding the pathophysiological basis the aforementioned collection of symptoms.

ACE2 mediated dysregulation of sodium dependent glucose transporter (SGLT1 or SLC5A1) in the intestinal epithelium also links it to the pathogenesis of diabetes mellitus which can be a possible reason for the associated mortality in COVID-19 patients with diabetes. High expression of ACE2 in mucosal cells of the intestine and GB make these organs potential sites for the virus entry and replication. Continued replication of the virus at these ACE2 enriched sites may be a basis for the disease recurrence reported in some, thought to be cured, patients. Based on the human tissue specific distribution of SARS-CoV-2 cell entry factors ACE2 and TMPRSS2 and other supportive evidence from the literature, we hypothesize that SARS-CoV-2 host cell entry receptor—ACE2 based mechanism in GI tissue may be involved in COVID-19 (i) in the pathogenesis of digestive symptoms, (ii) in increased diabetic complications, (iii) in disease recurrence.
Introduction

The world is currently reeling in an alarming outbreak of novel coronavirus disease 2019 referred to as COVID-19. COVID-19 is caused by a new coronavirus strain severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)—a positive sense single strand RNA virus. Recent studies which decoded structure of the virus showed binding of its S-spike protein to a human protein-angiotensin converting enzyme 2 (ACE2) [1–3]. Following ACE2 binding, cleavage of the viral spike protein (S) by the serine proteases like transmembrane serine protease 2 (TMPRSS2) or Cathepsin L (CTSL) is essential to effectuate host cell membrane fusion and virus infectivity [4]. Clinical presentation in COVID-19 patients is highly diverse and majority of them primarily presents with pulmonary symptoms (cough, fever, shortness of breath) [5]. In addition, some of the patients present with digestive symptoms like diarrhea, nausea, vomiting and abdominal pain (data ranges from 3.8% to 50.5%) [6]. Digestive symptoms have been the only presentations in some of the patients [7–9]. Digestive symptoms are not unique to the COVID-19 and usually present in the gastroenteritis caused by many other respiratory syndrome viruses like SARS-CoV-1 and influenza A and B [10,11]. However, how SARS-CoV-2 makes entry into the gastrointestinal (GI) tissue leading to gastroenteritis-like features, does not imbibe sufficient and coherent explanation in the light of the existing literature. Some investigators have speculated a fecal-oral route of transmission based on fecal shedding of viral proteins and infectious virus in some COVID-19 patients [12,13].

Knowing the expression pattern of ACE2 and one of the proteases, TMPRSS2 in gastrointestinal tract (GIT) may explicate the pathogenesis of digestive symptoms in COVID-19. Digestive juices and enzymes secreted from the liver, gall bladder (GB) and pancreas play an important role in maintenance of the secretions and absorption of nutrients across intestinal epithelium. Hence their possible dysfunction in COVID-19 patient needs to be examined in order to understand pathogenesis of the digestive symptoms which, in turn, prevent some COVID-19 associated mortality. Existing literature on the role of ACE2 in regulation of ion transporters which maintain secretion/absorption across intestinal epithelium provide a clue that digestive symptoms in COVID-19 may have an ACE2 based etiogenesis [11,14–16]. Investigating the ACE2 expression pattern of digestive system components may also help to explain exacerbated diabetic complications and mortality in COVID-19 patients. Diabetes has been noted as a co-morbidity (16.2%) in COVID-19 [5]. In addition, some of the patients present with digestive symptoms like diarrhea, nausea, vomiting and abdominal pain (data ranges from 3.8% to 50.5%) [6]. Digestive symptoms have been the only presentations in some of the patients [7–9]. Digestive symptoms are not unique to the COVID-19 and usually present in the gastroenteritis caused by many other respiratory syndrome viruses like SARS-CoV-1 and influenza A and B [10,11]. However, how SARS-CoV-2 makes entry into the gastrointestinal (GI) tissue leading to gastroenteritis-like features, does not imbibe sufficient and coherent explanation in the light of the existing literature. Some investigators have speculated a fecal-oral route of transmission based on fecal shedding of viral proteins and infectious virus in some COVID-19 patients [12,13].

Existing literature on the role of ACE2 in regulation of the ion transporters which maintain secretion/absorption across intestinal epithelium provide a clue that digestive symptoms in COVID-19 may have an ACE2 based etiogenesis [11,14–16]. Investigating the ACE2 expression pattern of digestive system components may also help to explain exacerbated diabetic complications and mortality in COVID-19 patients. Diabetes has been noted as a co-morbidity (16.2%) in COVID-19 and has contributed to increased mortality (22%) [17]. Existing literature implicates ACE2 mediated dysregulation of sodium dependent glucose transporter (SGLT1 or SLC5A1) at intestinal epithelium in the pathogenesis of the diabetes mellitus [18,19].

Many incidences of disease recurrence have been reported in COVID-19 patients even after being discharged from the hospital. Studies have reported continued shedding of SARS-CoV-2 in the feces of COVID-19 patients up to five weeks after disappearance of the pulmonary symptoms bolstering the indication that a residual persisting of virus inside the digestive system components may be a reason for the disease recurrence [20]. The tissue specific expression of ACE2 and TMPRSS2 in the digestive system components can effectively inform on whether any of these tissues can be involved in the continued replication of the SARS-CoV-2 after pulmonary symptoms are relieved.

Hypothesis

SARS-CoV-2 host cell entry receptor—ACE2 based mechanism in GI tissue may be involved in COVID-19:

1. In the pathogenesis of digestive symptoms.
2. In increased diabetic complications.
3. In disease recurrence.

Evaluation of hypothesis

ACE2 is a homologue of angiotensin-I converting enzyme (ACE), the key enzyme of the renin-angiotensin system (RAS). It is an integral membrane protein and localizes predominantly at the apical surface of polarized epithelial cells where it is proteolytically cleaved within its ectodomain to release a soluble form [21,22]. Currently, SARS-CoV-2 mediated binding of ACE2 and the following downstream events leading to tissue damage are little known. Presumptive understanding of SARS-CoV-2 driven pathology is being borrowed from SARS-CoV-1 which was the etiological basis of SARS pandemic in 2003. Uniquely, it acted on the same receptor as SARS-CoV-2 and led to many clinical manifestations similar to COVID-19 [23]. Studies utilizing cell lines to decipher SARS pathology in lung tissue showed that the spike protein of SARS-CoV-1 (SARS-S) induced TNFα production which facilitated virus entry [24]. TNFα also led to inflammation of the cell membrane and consequently tissue damage [22–24]. SARS-CoV-1 was also showed to cause downregulation of ACE2 expression at the cell membrane level [22,25]. Existing literature support abundant expression of ACE2 in human GI tissue [26]. Recently, enriched expressions of ACE2 (and TMPRSS2) in enterocytes and mucus producing cells were shown using single cell m-RNA expression studies [27,28]. ACE2 is known to regulate sodium-dependent amino acid and glucose transporters in the enterocytes brush border which physiologically engage in the absorption of nutrients from the digested food, and maintain osmotic and electrolyte balance across the GI lining epithelium [11,14]. In a recent study Yan et al., 2020 showed that SARS-CoV-2 can bind to the complex of ACE2 with B0AT1(Slc6a19)—a major sodium dependent neutral amino acid transporter present in the epithelial lining of human intestine (and also in kidneys) [1,29]. The dysregulation of the intestinal ion transporters has been implicated in the pathophysiology of infectious diarrhea and malabsorption disorders [15,16]. Literature also suggests that a dysregulation of these transporters can ensue interleukin/cytokine mediated intestinal inflammation and can give rise to digestive symptoms [14]. An enhanced GI expression of ACE2 is known in inflammatory bowel diseases (IBDs) which present with similar symptoms as in COVID-19 patients [14,30].

ACE2 mediated dysregulation of SGLT1 and/or SLC5A1 at intestinal epithelium also links to the pathogenesis of diabetes mellitus [18,19]. The SGLT1 transporters are physiologically involved in active absorption of glucose across the intestinal epithelium and its virus binding receptor ACE2 mediated dysregulation may exacerbate the existing impaired glycemic control in COVID-19 patients with diabetes mellitus [19]. Sufficient data on glycemic control in COVID-19 patients is lacking for now, impaired glycemic control was stated as an independent risk factor predicting morbidity and mortality in SARS patients with diabetes mellitus [31].

Continued replication of the SARS-CoV-2 in the intestinal tissue may be a potential reason for the recurrence of SARS-CoV-2 in the light of the diagnostic tests as has been noted in some COVID-19 patients after being discharged from the hospital [32,33].

Empirical data

We examined Human Protein Atlas metadata (https://www.proteinatlas.org/humanproteome/sars-cov-2) for transcriptomic and proteomic expression of ACE2 and TMPRSS2 in the components of human digestive system (including liver, GB, and pancreas) in tissues derived from the healthy individuals to understand pathophysiological basis of the digestive symptoms in COVID-19 patients. Further, we constructed a digestive system specific functional enrichment map of ACE2 gene using g: profiler (https://biit.cs.ut.ee/gprofiller/gost) utility and viewed with Cytoscape software, version 3.7.2 (https://cytoscape.org/). (The details of the assays and annotation used by the Human Protein Atlas can be accessed at: https://www.proteinatlas.org/about/assays+annotation#ihk). Furthermore, we consulted published
The transcriptomic and proteomic expression of ACE2 displayed high enrichment in the lower GIT (small intestine, colon, and rectum) ([Figs. S1, S2e–h, Table S1]). It was highest in the parts of small intestine followed by the colon and the rectum, and nearly absent (negligible/low mRNA expression and undetectable protein expression) in the upper GIT components: mouth cavity (including tongue, oral mucosa, and salivary glands), esophagus, and stomach ([Figs. S1, S2a–d]). GB showed high glandular expression of ACE2, while any protein expression was undetectable in appendix, liver (hepatocytes and bile duct), and pancreas (exocrine and endocrine glandular tissue) (though minimal mRNA expression was noted) ([Fig. S3]). Intense ACE2 expression was noted in the glandular cells as well as in the enterocytes in the lining epithelium of the lower GIT ([Fig. S2e-h]). The cellular expression of ACE2 was visible in the enterocyte cytoplasm and in the apical brush border ([Fig. S2e-h, marked with arrow heads]). The digestive system specific functional enrichment map for ACE2 gene were related to digestive functions like enzyme activity, amino acids transport, and peptide metabolism at the brush border membrane of enterocytes in the intestinal epithelium ([Fig. S4, Table S2]). TMPRSS2 was found enhanced in GIT and exocrine glands of pancreas ([Fig. S1, Table S2]) and found co-localized with ACE2 in enterocytes ([Fig. S5]).

Enriched expression of SARS-CoV-2 binding receptor ACE2 in the mucosal glands and enterocytes (including brush border cells) in the lining epithelium ([Fig. S2e-h, Table S1]) of the lower GIT indicates that GI cells are potential sites for virus replication. Evidence of the viral shedding in the feces shown in some studies indicates possible replication of the virus inside the GI cells which, in turn may explain GI manifestations of COVID-19 in addition to disease recurrence [34,35]. Recent in situ studies using recombinant strain of SARS-CoV-2 showed that the virus can potentially infect and replicate in human intestinal tissue [36,37]. Further, GIT to pulmonary spread of SARS-CoV-2 infection has been indicated by a study by Sun et al who showed in a transgenic mouse expressing human ACE2 that a direct intra-gastric inoculation of SARS-CoV-2 can cause productive infection and lead to pulmonary pathological changes [38].

Consequences of the hypothesis and discussion

**Hypothesis 1. Pathogenesis of digestive symptoms in COVID-19**

We found enriched transcriptomic and proteomic expression of SARS-CoV-2 binding receptor ACE2 in lower GIT (small intestine, colon, and rectum) and GB ([Figs. S1–3, Table S1]). The digestive system specific functional enrichment map of the ACE2 gene suggests its role in regulating secretory/absorptive functions at the brush border membrane of the enterocytes in the intestinal lining epithelium ([Fig. S4, Table S2]). The co-localized expression of SARS-CoV-2 cell entry associated protease TMPRSS2 in the enterocytes make these cells potential sites for viral infection ([Fig. S1, S5, Table S1]).

How the virus reaches the GI is arguable? Some authors speculated a fecal-oral route of entry [81]. Shedding of infectious SARS-CoV-2 in feces was also detected in occasional COVID-19 patients [12,13]. We examined possibility of this route of entry based on the expression pattern of ACE2 along the length of the GIT ([Figs. S1 and S2, Table S1]). Negligible or very low mRNA expression and undetectable proteomic expression of ACE2 in the mouth cavity (including tongue, oral mucosa, and salivary glands), esophagus, and stomach ([Fig. S1, S2a–d, Table S1]) indicate these parts of GIT can be resistant for the virus entry. But this observation does not negate a possible site of virus entry through the ACE2 receptors present in the lower GIT in case of fecal-oral transmission. It is then intriguing that how SARS-CoV-2 survives extremes of pH within the digestive system milieu (gastric: 1.5 to 3.5, pancreatic: 7.5, bile acid:7–8) while passing along the length of GIT. Recently, Chin et al., 2020 showed in vitro that SARS-CoV-2 can survive at wide range of pH values at room temperature (pH3-10) [39]. This can be further explained by an earlier study by Hirose et al, who, in an experimental, model demonstrated that RNA viruses like influenza A and B (when swallowed) can survive extremes of pH and maintain infectivity with help of the mucus cover lining GIT allowing their safe passage and even excretion in feces [40]. Mucus cells are abundant all along the length of the GIT which can contribute to the carriage and survival of SARS-CoV-2 thereby contributing to the so hypothesized fecal-oral transmission. This also hints that shedding of the virus in feces always may not be indicative of its replication in GI cells; all those patients who shed virus in stools don’t necessarily present with digestive symptoms [34].

Healthy intestinal mucosa may not be well conducive for the entry of the virus due to the presence of unique multi-layer barrier system, though a prior inflammatory condition which disrupts mucosal barrier may render the lower GI entry of the SARS-CoV-2 using ACE2 receptor and its replication inside tissue plausible [41]. Inflammatory conditions in GIT enhance the expression of ACE2 in the luminal epithelium which can provide additional support for the entry of the virus [42]. Once inside the GI cells, the virus can replicate there and may orchestrate viral toxin mediated cell injury ensuing further inflammation, thereby, giving rise to gastroenteritis like symptoms (diarrhea, nausea, and vomiting, abdominal pain) [22,24,43]. Other than the fecal-oral route, an alternative route of viral entry to the GI cells may be through the tissue microvasculature. Though this may not be highly probable but this premise does warrant consideration. In that case, fecal viral shedding can happen after sloughing of the inflamed/necrosed intestinal mucosa. Currently, data is limited which support presence of SARS-CoV-2 in the blood, however such evidence is available for other coronaviruses infections like SARS and MERS [32,34,44,45]. Based on the GI specific distributions of SARS-CoV-2 cell entry factors (ACE2 and TMPRSS2) and other supportive evidence from the literature, we propose that a virus binding-ACE2 mediated dysregulation of the sodium dependent nutrient transporters may be a plausible basis for the digestive symptoms in COVID-19. Prior intestinal inflammatory conditions like IBD may raise the susceptibility of SARS-CoV-2 infection through fecal-oral transmission.

**Hypothesis 2. Increased diabetic complications**

Recent studies reported prominent glycemic changes including new onset of diabetes and increased complications in some COVID-19 patients [46,47]. Increased mortality linked with complications has been frequent in diabetic patients with COVID-19 [17]. ACE2 mediated downregulation of SGLT1 in intestinal epithelium prevents hyperglycemia in rat models of the diabetes mellitus [48,49]. Though direct evidence is lacking in terms of the effect of SARS-CoV-2 binding on ACE2 on its signaling cascades, however, substantiation from SARS-CoV-1 studies (for SARS) suggests that it can downregulate ACE2 expression [25]. Such an eventuality can lead to upregulation of SGLT1 thereby precipitating hyperglycemia [48,49]. (SGLT1 inhibitors are being used in treatment of diabetes mellitus, their use in COVID-19 patients may need a rethinking for the dose adjustments [50].)

Apart from intestine SGLT1 is known to be widely expressed in other human tissues like proximal tubule of kidney, heart, and liver (proteinatlas.org/ENSG000001000170-SLC5A1/tissue) where it regulates the glucose absorption. An ACE2-mediated dysregulation of SGLT1 in COVID-19 patients warrants further investigation.

**Hypothesis 3: Disease recurrence**

Abundant expression of ACE2 and TMPRSS2 in GI lumen epithelial cells indicates these are potential site for viral replication in COVID-19 patients. A persistence of SARS-CoV-2 infection in GI tissue can be a reason for disease recurrence in the light of the diagnostic tests as has been noted in some COVID-19 patients after being discharged from the hospital [32,33]. A post-mortem study of these organs in COVID-19 patients may provide some confirmation in this regard.
Interestingly, high expression of ACE2 in glandular cells of the GB gives an insight that this can be a hidden site for continued virus replication. In contrast, we found low m-RNA and undetectable proteomic expression of TMPRSS2 in glandular cells of GB, however, robust expression of another serine protease CTSL2 were noted in these cells in the records of Human Protein Atlas [51], which may be able to substitute for TMPRSS2 [1].

GB has a luminal connection to the duodenum through cystic and common bile duct (CBD). Though this connection is guarded by a sphincter (of Oddi) present in duodenal mucosa, it doesn’t create an anatomical barrier and, therefore, a viral invasion along the mucosal epithelium remains a possibility.

GB is the physiological storage site for the bile secreted from the hepatocytes, and pathology of this organ can also contribute to the digestive symptoms present in COVID-19 patients. GB has been a known reservoir for Salmonella typhi, a bacterium causing enteric fever, and one of the cited reasons for disease recurrence [52]. The thick mucin secreted from its glandular cells can provide a protective environment for survival of SARS-CoV-2 (as we discussed above for GI lining epithelium) [40]. Hence, GB homing may act as a mechanism for the replication of the virus even without ensuing a local tissue injury.

Conclusions

Based on the observed pattern of tissue specific expression of SARS-CoV-2 host cell entry factors ACE2 and TMPRSS2 in the components of the digestive system in normal individuals, we propose that an ACE2 based mechanism may be involved in the pathogenesis of digestive symptoms, increased diabetic complications, and disease recurrence in COVID-19.

Limitations and future directions

All the aspects of the plausible SARS-CoV-2 binding receptor ACE2 mediated pathology in the digestive system which we have discussed above are based on the distribution of the virus cell entry related factors in the normal tissue, hence, a validation in actual patients will be necessary before reaching any conclusion. Further studies are advisable to understand the molecular mechanisms involved in the SARS-CoV-2 binding receptor ACE2 mediated dysregulation of the intestinal nutrient transporters and finding out COVID-19 specific drug targets. Interindividual variations in frequency of the digestive symptoms, diabetes associated mortality, and recurrences may depend upon the genotype specific variations in ACE2 expression and other patient specific characteristics (like age, sex, and comorbidity). A study of these variables in the disease pathogenesis may help in deciding personalized therapeutic management for the COVID-19 cases.

Author contributions

AK conceived the idea. AK wrote the first draft. MAF, VP, KR, MK, CK, KK, PK, PP, HN, RKN, SNP, RQ, and SK revised the draft. RKN, KR, PP, PK, and VP contributed to data analysis, and prepared tables and figures.

Funding

There was no dedicated funding for this project.

Data Availability

Data used for this study can be accessed at the following link: https://www.proteinatlas.org/about/download.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.

Acknowledgments

The authors acknowledge The Human Protein Atlas (https://www.proteinatlas.org/) for ready availability of data in the public domain. This manuscript has been released as a pre-print at BioRxiv [https://doi.org/10.1101/2020.04.14.040204, Kumar A, et al. [53]].

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.mehy.2020.110271.

References

[1] R. Yan Y. Zhang Y. Li X. Xia Y. Guo Q. Zhou Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 Science 367 6485 2020 doi:10.1126/sci- ence.abb2762.
[2] Shang J. Ye G. Shi K. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020. https://doi.org/10.1038/s41586-020-2179-y.
[3] Walls AC. Park YJ. Tortorici MA. Wall A. McGuire AT. Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020. pii: S0092-8674(20)30262-2. doi: 10.1016/j.cell.2020.02.059.
[4] Hoffmann M. Kleine-Weber H. Schroeder S. Krüger N. Hutter T. Erichsen S. et al. SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181(271–280):e28 https://doi.org/10.1016/j.cell.2020.02.052.
[5] Guan WJ. Ni ZY. Hu Y. et al. Clinical characteristics of coronavirus disease in China. N Engl J Med 2020;382(11):1708–1717. https://doi.org/10.1056/NEJMoa2002022.
[6] Pan L. Mu M. Yang P. Sun Y. Wang R. Yan J. et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China. Am J Gastroenterol 2020;115:1. https://doi.org/10.14309/ajg.0000000000000620.
[7] Pan L. Mu M. Ren HG. Yang P. Sun Y. Wang R. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol 2020;20. https://doi.org/10.14309/ajg.0000000000000620.
[8] Hindson J. COVID-19: faecal–oral transmission? Nat Rev Gastroenterol Hepatol 2020;1–1. https://doi.org/10.1038/s41575-020-0295-7.
[9] Minodier L. Charrel RN. Ceccaldi PE. et al. Prevalence of gastrointestinal symptoms in patients with influenza, clinical significance, and pathophysiology of human influenza viruses in faecal samples: what do we know? Virol J 2015;12(1):215. https://doi.org/10.1186/s12985-015-0448-4.
[10] Leung WK. To KF. Chan PK. et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology 2003;125(4):1011–7. https://doi.org/10.1053/gast.2003.50855003001215-0.
[11] Bror S. Fairweather SJ. Amino acid transport across the mammalian intestine. Comp Physiol 2011;9(1):343–73. https://doi.org/10.1002/cphy.c170041.
[12] Zhang Y. Chen C. Zhu S. Shu C. Wang D. Song J. Song Y. Zhen W. Feng Z. Wu G. et al. Isolation of 2019 nCoV from a Sool Specimen of a Laboratory-Confirmed Case of the Coronavirus Disease 2019 (COVID-19). China CDC Weekly, 2020, Vol 2, Issue 8. Pages 123-124 (2020) 2:123–124. doi:10.46234/CCDC2W2020.033.
[13] F. Xiao J. Sun Y. Xu F. Li X. Huang H. Li et al. Infectious SARS-CoV-2 in Feces of Patients with Severe COVID-19 Emerg Infect Dis 26 2020 doi:10.3201/infdis.200681.
[14] Hashimoto T. Perlot T. Rehman A. et al. ACE2 links amino acid malnutrition to microbial intestinal and ecological inflammation. Nature 2012;487(7408):477–81. https://doi.org/10.1038/nature11288.
[15] Das S. Jayaratne R. Barrett KE. The role of ion transporters in the pathophysiology of infectious diarrhea. Cell Mol Gastroenterol Hepatol 2018;6(1):33–45. https://doi.org/10.1016/j.jcmgh.2018.02.009.
[16] Milne MD. Disorders of intestinal amino-acid transport. J Clin Pathol Suppl (R Coll Pathol) 1971;5:41–4.
[17] Fang L. Karakikalsi G. Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020;8(4):2151–2156. https://doi.org/10.1016/S2213-2600(20)30316-8.
[18] Bindon SM. Lazariguves E. The swooper side of ACE2: physiological evidence for a role in diabetes. Mol Cell Endocrinol 2009;302(2):193–202. https://doi.org/10.1016/j.mce.2008.09.020.
[19] Navale AM, Paranjape AN. Glucose transporters: physiological and pathological roles. Biophys Rev 2016;8:1(3–9. https://doi.org/10.1007/s12551-015-0186-2.
[20] Wu Y. Guo C. Tang L. et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol 2020;5(5):434–5. https://doi.org/10.1016/S2568-1253(20)30093-2.
[21] Ren X. Glende J. Al-Falah M. et al. Analysis of ACE2 in polarized epithelial cells.
surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus. J Gen Virol 2006;87(6):1691–5. https://doi.org/10.1099/vir.0.81749.0.

(22) Jia HP, Look DC, Tan P, et al. Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. Am J Physiol Lung Cell Mol Physiol 2009;297(1):L84–96. https://doi.org/10.1152/ajplung.00071.2009.

(23) Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect 2020;30:1071–3. https://doi.org/10.1016/j.cmi.2020.03.026. pii: S1198-743X(20).

(24) Haga S, Yamamoto N, Nakai-Murakami C, et al. Modulation of TNF-a-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry. Proc Natl Acad Sci USA 2008;105(22):7809–14. https://doi.org/10.1073/pnas.0711241105.

(25) Kuba K, Imay I, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005;11(8):875–9. https://doi.org/10.1038/nm1267.

(26) Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203(2):631–7. https://doi.org/10.1002/path.1570.

(27) Sungnak W, Huang N, Beacain C, Berg M, Queen R, Litvinukova M, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med 2020;1:1–7. https://doi.org/10.1038/s41591-020-0868-6.

(28) C. Muus M.D. Luecken G. Eraslan A. Waghray G. Heimberg L. Sikkema et al. SARS-CoV-2 related proteins-The Human Protein Atlas. Available at: https://www.proteinatlas.org/humanproteome/sars-cov-2 [Accessed June 1, 2020].

(29) Jia HP, Look DC, Tan P, et al. Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. Am J Physiol Lung Cell Mol Physiol 2009;297(1):L84–96. https://doi.org/10.1152/ajplung.00071.2009.

(30) Haga S, Yamamoto N, Nakai-Murakami C, et al. Modulation of TNF-a-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry. Proc Natl Acad Sci USA 2008;105(22):7809–14. https://doi.org/10.1073/pnas.0711241105.

(31) Yang JK, Feng Y, Yuan MY, et al. Viral RNA in blood as indicator of severe outcome in Middle East respiratory syndrome coronavirus infection. Emerg Infect Dis 2016;22(10):1813. https://doi.org/10.3201/eid2210.160218.

(32) Gu J, Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol 2007;170(4):1136–47. https://doi.org/10.2353/ajpath.2007.061080.

(33) Chang L, Yan Y & Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev 2020. pii: S0887-7963(20)30014-6. doi: 10.1016/j.tmrv.2020.02.002.

(34) Chan LKY, Leung PS. Multifaceted interplay among mediators and regulators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells bioRev 2020 04 2020 pp. 19.049254 10.1101/2020.04.19.049254.

(35) Kim SY, Park SJ, Cho SY, et al. Viral RNA in blood as indicator of severe outcome in Middle East respiratory syndrome coronavirus infection. Emerg Infect Dis 2016;22(10):1813. https://doi.org/10.3201/eid2210.160218.

(36) Chang L, Yan Y & Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev 2020. pii: S0887-7963(20)30014-6. doi: 10.1016/j.tmrv.2020.02.002.

(37) Kim SY, Park SJ, Cho SY, et al. Viral RNA in blood as indicator of severe outcome in Middle East respiratory syndrome coronavirus infection. Emerg Infect Dis 2016;22(10):1813. https://doi.org/10.3201/eid2210.160218.

(38) Kim SY, Park SJ, Cho SY, et al. Viral RNA in blood as indicator of severe outcome in Middle East respiratory syndrome coronavirus infection. Emerg Infect Dis 2016;22(10):1813. https://doi.org/10.3201/eid2210.160218.

(39) Chang L, Yan Y & Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev 2020. pii: S0887-7963(20)30014-6. doi: 10.1016/j.tmrv.2020.02.002.

(40) Kim SY, Park SJ, Cho SY, et al. Viral RNA in blood as indicator of severe outcome in Middle East respiratory syndrome coronavirus infection. Emerg Infect Dis 2016;22(10):1813. https://doi.org/10.3201/eid2210.160218.

(41) Chang L, Yan Y & Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev 2020. pii: S0887-7963(20)30014-6. doi: 10.1016/j.tmrv.2020.02.002.

(42) Kim SY, Park SJ, Cho SY, et al. Viral RNA in blood as indicator of severe outcome in Middle East respiratory syndrome coronavirus infection. Emerg Infect Dis 2016;22(10):1813. https://doi.org/10.3201/eid2210.160218.

(43) Chang L, Yan Y & Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev 2020. pii: S0887-7963(20)30014-6. doi: 10.1016/j.tmrv.2020.02.002.

(44) Chang L, Yan Y & Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev 2020. pii: S0887-7963(20)30014-6. doi: 10.1016/j.tmrv.2020.02.002.

(45) Chang L, Yan Y & Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev 2020. pii: S0887-7963(20)30014-6. doi: 10.1016/j.tmrv.2020.02.002.

(46) Chang L, Yan Y & Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev 2020. pii: S0887-7963(20)30014-6. doi: 10.1016/j.tmrv.2020.02.002.

(47) Chang L, Yan Y & Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev 2020. pii: S0887-7963(20)30014-6. doi: 10.1016/j.tmrv.2020.02.002.

(48) Chang L, Yan Y & Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev 2020. pii: S0887-7963(20)30014-6. doi: 10.1016/j.tmrv.2020.02.002.

(49) Chang L, Yan Y & Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev 2020. pii: S0887-7963(20)30014-6. doi: 10.1016/j.tmrv.2020.02.002.

(50) Chang L, Yan Y & Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev 2020. pii: S0887-7963(20)30014-6. doi: 10.1016/j.tmrv.2020.02.002.

(51) Chang L, Yan Y & Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev 2020. pii: S0887-7963(20)30014-6. doi: 10.1016/j.tmrv.2020.02.002.